Marshall Wace North America L.P. Invests $17.80 Million in Becton, Dickinson and Company (BDX)

Marshall Wace North America L.P. bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 97,286 shares of the medical instruments supplier’s stock, valued at approximately $17,804,000.

Other institutional investors have also recently made changes to their positions in the company. Quadrature Capital Ltd purchased a new position in shares of Becton, Dickinson and during the fourth quarter valued at about $944,000. Teachers Advisors LLC increased its position in shares of Becton, Dickinson and by 1.8% in the fourth quarter. Teachers Advisors LLC now owns 346,573 shares of the medical instruments supplier’s stock worth $57,375,000 after buying an additional 5,995 shares in the last quarter. Macquarie Group Ltd. increased its position in shares of Becton, Dickinson and by 16.0% in the fourth quarter. Macquarie Group Ltd. now owns 67,709 shares of the medical instruments supplier’s stock worth $11,209,000 after buying an additional 9,340 shares in the last quarter. Toth Financial Advisory Corp increased its stake in Becton, Dickinson and by 2.2% in the first quarter. Toth Financial Advisory Corp now owns 23,478 shares of the medical instruments supplier’s stock worth $4,307,000 after buying an additional 509 shares during the period. Finally, Private Asset Management Inc. acquired a new stake in Becton, Dickinson and during the first quarter worth $956,000. 75.57% of the stock is owned by hedge funds and other institutional investors.

Shares of Becton, Dickinson and Company (BDX) opened at 197.69 on Friday. The firm has a market capitalization of $44.99 billion, a P/E ratio of 57.25 and a beta of 1.05. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $206.63. The stock has a 50 day moving average of $199.72 and a 200-day moving average of $188.69.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.44 by $0.02. The business had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm’s revenue for the quarter was down 5.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.35 EPS. On average, equities analysts expect that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be issued a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a yield of 1.48%. The ex-dividend date is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.com-unik.info/2017/08/19/marshall-wace-north-america-l-p-invests-17-80-million-in-becton-dickinson-and-company-bdx-updated-updated.html.

A number of equities research analysts recently weighed in on the stock. Barclays PLC reissued an “equal weight” rating and set a $210.00 price target (up from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. BidaskClub cut shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Zacks Investment Research cut shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, May 4th. Stifel Nicolaus reiterated a “buy” rating on shares of Becton, Dickinson and in a report on Wednesday, August 9th. Finally, Evercore ISI upgraded shares of Becton, Dickinson and from an “in-line” rating to an “outperform” rating and upped their price target for the company from $186.00 to $200.00 in a report on Monday, April 24th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Becton, Dickinson and presently has an average rating of “Buy” and an average price target of $195.79.

In related news, EVP Ribo Alberto Mas sold 7,463 shares of the business’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $201.41, for a total transaction of $1,503,122.83. Following the completion of the transaction, the executive vice president now owns 29,323 shares in the company, valued at approximately $5,905,945.43. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Nabil Shabshab sold 6,149 shares of the business’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $201.76, for a total value of $1,240,622.24. Following the transaction, the insider now owns 15,648 shares of the company’s stock, valued at approximately $3,157,140.48. The disclosure for this sale can be found here. Insiders have sold a total of 57,631 shares of company stock valued at $11,112,178 in the last 90 days. 1.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

What are top analysts saying about Becton Dickinson and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Becton Dickinson and Company and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit